Brought to you by 
Eisai, Verastem develop Wnt inhibitors against cancer
14 May 2013
Executive Summary
Eisai Co. Ltd. will partner with start-up Verastem Inc. (cancer therapeutics) in a collaboration to generate small-molecule Wnt inhibitors that target cancer stem cells (CSCs), a primary cause of tumor recurrence and metastasis.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Tools
-
Molecular Diversity
- Natural Products
-
Molecular Diversity
-
Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
- Reverse Licensing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Eisai, Verastem develop Wnt inhibitors against cancer
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice